

PHARMACEUTICAL NANOTECHNOLOGY & NANOMEDICINE

March 20 - 21, 2019 | New York, USA

WORKSHOP | DAY 2

JOURNAL OF NANOMEDICINE & NANOTECHNOLOGY 2019, VOLUME 10 | DOI: 10.4172/2157-7439-C1-100

Formulation development and *in-vitro* characterization of orodispersible tablets of Piroxicam and Lidocaine HCl for use in dental pain

The purpose of this research study was formulation development and *in-vitro* characterization of orodispersible tablets of Piroxicam and Lidocaine HCl along with the development and validation of the novel method of simultaneous estimation of both the drugs on HPLC. The aim was to develop a product that will provide immediate relief from the pain of dental origin, due to the local action of lidocaine in the mouth and also produce long-lasting analgesia by piroxicam after

absorption. Orodispersible tablets of Piroxicam and Lidocaine HCl were developed by direct compression method. FTIR spectroscopy was used to study drug-drug and drugs-exipients compatibility. The FTIR spectra showed that there was no interaction between the two drugs and also between the drugs and excipients which proved that all the ingredients are compatible. The assay method for simultaneous estimation of both the drugs on HPLC was developed successfully. The developed method was also validated by following ICH guidelines.

Biography

Muhammad Shahid Khan has got more than 18 years of experience in the pharmaceutical industry in different posts. He is currently working as Plant Manager in NovaMed Pharmaceuticals (Pvt) Ltd., a local firm but also manufacturing products for



Muhammad Shahid Khan
NovaMed Pharmaceuticals (Pvt) Ltd.,
Pakistan

many multinational companies like Sanofi Aventis, ICI, Getz Pharma, and Searle. He is overall responsible for the whole plant. He has attended many training workshops, exhibitions and technical seminars in Pakistan and abroad. He has got training from France. He has visited many countries of the world for training and to attend exhibitions.

shahid.khan@novamed.com.pk